Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects
NCT00765856
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
27
Enrollment
INDUSTRY
Sponsor class
Stopped
Terminated new protocol developed which incorporated Pharmacokinetics
Conditions
Chronic Pain
Interventions
DRUG:
Oxymorphone ER
Sponsor
Endo Pharmaceuticals